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Abstract
Background: According to World Health Organization (WHO) prevalence estimates, 1.1 million people in Mexico are
infected with Trypanosoma cruzi, the etiologic agent of Chagas disease (CD). However, limited information is available about
access to antitrypanosomal treatment. This study assesses the extent of access in Mexico, analyzes the barriers to access,
and suggests strategies to overcome them.
Methods and Findings: Semi-structured in-depth interviews were conducted with 18 key informants and policymakers at
the national level in Mexico. Data on CD cases, relevant policy documents and interview data were analyzed using the
Flagship Framework for Pharmaceutical Policy Reform policy interventions: regulation, financing, payment, organization,
and persuasion. Data showed that 3,013 cases were registered nationally from 2007–2011, representing 0.41% of total
expected cases based on Mexico’s national prevalence estimate. In four of five years, new registered cases were below
national targets by 11–36%. Of 1,329 cases registered nationally in 2010–2011, 834 received treatment, 120 were pending
treatment as of January 2012, and the treatment status of 375 was unknown. The analysis revealed that the national
program mainly coordinated donation of nifurtimox and that important obstacles to access include the exclusion of
antitrypanosomal medicines from the national formulary (regulation), historical exclusion of CD from the social insurance
package (organization), absence of national clinical guidelines (organization), and limited provider awareness (persuasion).
Conclusions: Efforts to treat CD in Mexico indicate an increased commitment to addressing this disease. Access to
treatment could be advanced by improving the importation process for antitrypanosomal medicines and adding them to
the national formulary, increasing education for healthcare providers, and strengthening clinical guidelines. These
recommendations have important implications for other countries in the region with similar problems in access to
treatment for CD.
Citation: Manne JM, Snively CS, Ramsey JM, Salgado MO, Ba¨rnighausen T, et al. (2013) Barriers to Treatment Access for Chagas Disease in Mexico. PLoS Negl Trop
Dis 7(10): e2488. doi:10.1371/journal.pntd.0002488
Editor: Carlos Franco-Paredes, Emory University, United States of America
Received February 19, 2013; Accepted September 2, 2013; Published October 17, 2013
Copyright:  2013 Manne et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: We would like to thank the David Rockefeller Center for Latin American Studies and the Harvard Global Health Institute for generously supporting this
research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jmanne@post.harvard.edu
Introduction
Chagas disease is a vector-borne, parasitic disease with a
prevalence of 8 million infections globally. The disease is
responsible for as many as 15,000 deaths per year [1,2], largely
concentrated among the poor in Latin America, and a recent
study found that the disease is also responsible for substantial losses
in productivity and a large economic burden, especially in high
prevalence countries [3]. Trypanosoma cruzi, the etiologic agent of
Chagas disease, is most often transmitted by contact with infected
triatomine insects, though transmission can also occur congenitally
and through blood transfusion or organ transplantation [4]. In
2009, it was estimated that less than 1% of those infected with T.
cruzi received treatment for the disease globally [5].
According to prevalence estimates for 2006 from the World Health
Organization [6], approximately 1.1 million people are infected with
T. cruzi in Mexico. However, limited published information exists on
how many patients receive treatment in Mexico and what obstacles
may hinder access to treatment. This study sought to determine
for Mexico: (1) the extent of treatment access for Chagas disease; (2)
the national level barriers to access to treatment for Chagas; and (3)
strategies that could be used to overcome these barriers and
increase access to treatment for Chagas disease.
This study uses an existing health systems framework, the
Flagship Framework for Pharmaceutical Policy Reform [7], to
analyze the barriers to treatment access for Chagas disease in
terms of five policy interventions – regulation, financing, payment,
organization, and persuasion. Based on this analysis, we also
suggest strategies to increase access.
Diagnosis and treatment of Chagas disease
Chagas disease is clinically manifested in two stages – an acute
stage and a chronic stage. The acute stage lasts for approximately
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4–8 weeks and is characterized by flu-like symptoms or a
characteristic local swelling at the site of parasite entry [8,9],
following which an infected person enters the indeterminate form
of the chronic phase of infection. Among those with the
indeterminate chronic form, about 20–30% of patients progress
to the chronic cardiac or digestive forms of Chagas disease [10].
The most common course of Chagasic cardiomyopathy includes
conduction system abnormalities early in the disease, resulting in
heart failure. In all phases, serological tests such as the enzyme-
linked immunosorbent assay (ELISA) test, the indirect haemag-
glutination assay (IHA), and the indirect immunofluorescent
antibody test (IIF) are used for diagnosis [4,9,11]. Because these
tests can be difficult to interpret, the WHO recommends the use of
two concomitantly positive tests to make a confirmed diagnosis
[11,12].
Currently, benznidazole and nifurtimox are the only antitry-
panosomal medicines available to treat T. cruzi infection.
Antitrypanosomal therapy is strongly recommended by WHO
for acute, congenital or reactivated infections, and for chronic
infection in children under the age of 18 [13,14,15]. Recent
scientific evidence about the clinical effectiveness of these
medications has led to the expansion of treatment indications to
include adults in the chronic phase of the disease without
advanced cardiomyopathy [1,11,16,17,18,19]. Though no ran-
domized controlled trial has directly compared the two medica-
tions [11], WHO guidance and the clinical literature place greater
emphasis on the use of benznidazole [4] as a first-line therapy
because there is more clinical evidence for its efficacy, and it has a
more favorable side-effect profile and is better tolerated by adult
patients [9,15,16,17,18,20]. A randomized clinical trial of
benznidazole is underway to determine its efficacy in slowing
progression of disease among patients with early to moderate stage
Chagasic cardiomyopathy [21,22].
Both benznidazole and nifurtimox have undergone changes to
their global supply chains over the past decade. Benznidazole was
manufactured by Roche until 2003, at which time the rights and
manufacturing technology were transferred to the Pernambuco
state pharmaceutical laboratory in Brazil, Laboratorio Farm-
aceutico do Estado Pernambuco (LaFepe) [23,24]. Between 2004
and 2006, LaFepe produced several batches of benznidazole using
active pharmaceutical ingredient that was donated by Roche [24].
Then, after a period of no production, LaFepe resumed
production of benznidazole in late 2011 and the medicine is
now distributed by several entities including LaFepe, WHO, and
Masters Pharmaceuticals. Nifurtimox is manufactured by Bayer
HealthCare in El Salvador. In 2007 Bayer reached an agreement
with WHO for Bayer to donate nifurtimox to WHO and for
WHO to distribute the medicine through the WHO-Bayer
Nifurtimox Donation Program [25].
Chagas disease and the Mexican health system
Access to treatment for Chagas disease in Mexico must be
considered in the context of the Mexican health system and its
recent reforms. Mexico has three major national insurance
schemes, the Instituto Mexicano del Seguro Social (IMSS), Instituto de
Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), and
Seguro Popular (SP) [26]. IMSS and ISSSTE together offered
coverage to approximately 42.6 million private sector (IMSS) and
public sector (ISSSTE) employees in 2010 [26]. As of 2011, SP, a
social health insurance program started in 2003, offers a package
of 284 essential services to approximately 51.8 million Mexicans,
according to the Mexican government [10,27,28,29]. Affiliation
with SP requires a fixed family contribution that is based on a
progressive scale by income, though individuals and families who
fall in the lowest two income deciles are exempt from payment of a
premium [26,27].
The national Program on Onchocerciasis, Leishmaniasis and
Chagas Disease within the Mexican Secretary of Health’s National
Center for the Prevention and Control of Diseases (CENA-
PRECE) is the unit responsible for establishing guidelines and
coordinating national activities for Chagas disease control. The
State Secretaries of Health report patients who are diagnosed by
ISSSTE, IMSS and SP systems to the national Program, which
then turn provides medicines to treat confirmed cases. Figure 1
shows the process of case registration for a patient with Chagas
disease.
Methods
Ethics statement
IRB exemption was obtained from Harvard School of Public
Health (Protocol# 21514-101) and the National Institute for
Public Health (INSP) located in Cuernavaca, Mexico. Oral
informed consent was obtained from all interviewees.
Theoretical framework
Defining and quantifying access. Access is an important
and frequently addressed theme in public health, and multiple
frameworks exist to define access and its possible determinants
[30,31]. In this study, we use a general definition of access as ‘‘the
ability to obtain and appropriately use a good quality health
technology when it is needed’’ [32].
Given that antitrypanosomal medicines are procured based on
the number of registered cases, we first quantify the number of
cases registered by CENAPRECE over the period of 2007–2011.
We then assess the extent of case registration for Chagas disease in
the following ways: (1) by comparing the number of cases
registered to the expected number of prevalent cases according
to the most recent (2010) estimate of Chagas disease prevalence
from the Mexican Secretary of Health (733,333 cases, 0.652%
prevalence); and (2) by comparing the number of cases registered
to the targets for new case registration that were established by the
national Program on Onchocerciasis, Leishmaniasis and Chagas
Author Summary
Chagas disease is a vector-borne disease caused by the
parasite Trypanosoma cruzi. The disease is most frequently
transmitted by triatomine insects but can also be passed
through blood donation or from mother to child at birth.
Experts estimate that 8 million people are infected with
Chagas disease globally and that 1.1 million of these
infections are found in Mexico. Most public health
programs for Chagas disease focus on preventing new
infections through vector control and screening the blood
supply. However, in recent years there has been a greater
focus on treating the disease with one of two available
medications, benznidazole or nifurtimox. This study
explores access to these two drugs in Mexico. The study
shows that less than 0.5% of those who are infected with
the disease received treatment in Mexico in years. The
study also identified important factors that limit access in
Mexico, including the exclusion of both drugs from the
national health insurance program and problems import-
ing these medications. Finally, the paper suggests ways
that these problems can be overcome in Mexico, while
providing helpful insight for other countries that struggle
with similar problems in treating this disease.
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Disease within CENAPRECE. We use the most recent estimate
from the Secretary of Health because it is the most conservative
estimate available. The details of prevalence estimates for Mexico
are summarized in Table 1.
Next, we examine the treatment status of cases registered in
the period 2010–2011 in terms of those who received treatment,
those who were pending treatment as of January 2012, and
‘‘others’’ whose treatment trajectory was unknown. We define
the gap in access as the number of cases registered in 2010–2011
that were treatment eligible but had not yet received treatment
with benznidazole or nifurtimox at the time of the study
(January 2012). Due to a lack of data, we were unable to
quantify the proportion of registered cases that were treatment
eligible and how this compares to the proportion that received
treatment. As a sub-analysis, we assess the clinical quality of
treatment access for patients; we define clinical quality as the
proportion of patients receiving treatment with benznidazole, the
first-line medication, as compared to those receiving treatment
with nifurtimox, the second-line medication. Although there is
no official WHO guideline that defines benznidazole as the first
line treatment, the use of benznidazole over nifurtimox is
supported by evidence in the literature detailing the clinical
effectiveness of benznidazole, its superior side effect profile, and
its sole use as the comparator in clinical trials [9,16,17,21,33].
We therefore adopt benznidazole treatment as our indicator of
clinical quality.
The Flagship Framework and access to treatment for
Chagas disease in Mexico. Given that treatment for Chagas
disease is provided in the context of the state and national
healthcare system, we sought a framework that could examine
Figure 1. Chagas disease diagnostic and treatment patient flow in Mexico.
doi:10.1371/journal.pntd.0002488.g001
Table 1. Prevalence estimates and case registration in
Mexico.
National Level
Population 112,340,000
Prevalence Estimate - Blood Bank Estimate 0.652%
Expected Cases - Blood Bank Estimate 733,333
Cases registered (2007–2011) 3,013
% of Target (2007–2011) 80.48%
% of Expected Cases - Blood Bank 0.41%
doi:10.1371/journal.pntd.0002488.t001
Treatment Access for Chagas Disease in Mexico
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access to Chagas medicines in the pharmaceutical sector, could
assess key institutions in the health system and their interactions,
and could be used to develop strategies for reform.
We use the Flagship Framework for Pharmaceutical Policy
Reform to analyze barriers to treatment access for Chagas disease
in Mexico. This Framework presents three ultimate performance
goals of the pharmaceutical sector: health status, citizen satisfac-
tion, and financial protection (Figure 2). These goals represent the
dependent variables in the framework, affected by five categories
of independent variables called the ‘‘control knobs’’ (hereafter
policy interventions) of financing, payment, organization, regula-
tion, and persuasion [7]. These policy interventions are linked to
the ultimate performance goals through three important charac-
teristics that describe the functioning of various subsystems of the
pharmaceutical sector. These three ‘‘intermediate performance
goals’’ are efficiency, access, and quality [7].
Our analysis in this paper centers on access, one of the three
intermediate performance goals, as the dependent variable of
interest; as a sub-analysis, the clinical quality of the treatment
received by patients is also partially addressed, according to the
definitions provided above. Access to antitrypanosomal treatment
as an intermediate performance goal can be linked to the ultimate
performance goal of health status via the established relationship
between treatment with antitrypanosomal therapy and improve-
ments in the health status of T. cruzi infected patients. It has been
shown that antitrypanosomal therapy with benznidazole or
nifurtimox prevents or slows the progression of chronic Chagas
disease and increases quality-adjusted life expectancy [16,17,18].
This paper’s definition of clinical quality, as the proportion of
patients receiving first-line treatment with benznidazole, is related
to the ultimate performance goal of health status because there is
greater evidence in the literature showing the clinical effectiveness
of benznidazole and the fact that it is better tolerated by patients,
and thus that it has a greater positive impact on health status. It is
important to note that data on treatment adherence or comple-
tion, which are also important for clinical quality, were not
available for patients who received either medicine.
We organize our analysis of barriers around the five policy
interventions as categories of independent variables that affect
access. We adopt the definitions for these policy interventions
directly from the Flagship Framework. Regulation refers to
government efforts to alter behavior in the private and to a lesser
extent the public sector by imposing rules that are backed by
sanctions. Payment focuses on what and how various organizations
and individuals in the pharmaceutical sector are paid and the
incentives created by those payments. Financing refers to how the
money for pharmaceuticals is raised and how this affects the
distribution of use and costs across the infected population.
Organization focuses on how activities in the pharmaceutical
sector are divided among public and private entities and
Figure 2. Flagship Framework for Pharmaceutical Policy Reform [7].
doi:10.1371/journal.pntd.0002488.g002
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centralized and decentralized agencies. Persuasion refers to
community engagement and efforts to convince specific actors
(doctors, patients, policymakers, etc.) to change certain behaviors
through education, social marketing, or health communication
activities [7]. In this analysis, regulation is discussed first because it
affects findings in other policy interventions.
Data collection. Guided by the Flagship Framework, we
created a list of possible obstacles to treatment access for Chagas
disease in Mexico [7,32]. Based on this initial assessment, we
constructed three interview guides: one for key informants, a
second for national level actors, and a third for state level actors.
We also searched the academic literature and public government
websites for national regulations, policies and laws relevant to the
topic of Chagas disease treatment in Mexico. This documentation
served as a source for triangulation of information obtained in
interviews.
Semi-structured in-depth interviews were conducted with 18
key informants and policymakers. Contact with initial interviewees
was established through in-country key informants. Subsequent
interviews were then obtained through a snowball sampling
method, whereby participants in the interviews facilitated contact
with other relevant actors [34]. The sampling strategy did not
specify a desired number of actors to be interviewed at each level,
but relied on the concept of saturation, such that interviews were
conducted until responses to the survey questions were repetitious
or until all relevant actors had been contacted [34].
Interviews were conducted by one member of the research team
(JM) in English or Spanish, depending on the preference of the
interviewee, and written notes were taken of interview responses.
In all interviews, written documentation of policies, procedures,
laws, or governmental permits mentioned by the interviewee were
requested if they were not already publicly available.
Data analysis. To answer our second research question on
the barriers to treatment access, we organized national regulations,
policies and laws as well as interview responses into categories
corresponding to the policy interventions in the Flagship
Framework for Pharmaceutical Policy Reform. Reliance on
multiple sources of written and oral information enabled
triangulation of the information obtained. This allowed us to
minimize bias that could be present in the responses of any one
source [35].
Results
Access to treatment for Chagas disease at the national
level
Registration of cases. The Secretary of Health in Mexico
reports that 3,013 cases of Chagas disease were registered by the
national Program on Onchocerciasis, Leishmaniasis and Chagas
Disease (hereafter national program) within CENAPRECE from
2007–2011. The number of cases registered represents approxi-
mately 0.41% of the total expected cases, according to Mexico’s
estimates of national prevalence [36,37]. Moreover, in every year
during this period but one (2008), the number of new registered
cases was below the national program’s target number for new
registered cases by 11–36% (Figure 3) [38]. The national targets
correspond to a 20% increase in registered cases per year,
beginning in 2006. These findings show that the number of new
cases registered by the national program is substantially below the
number of new registrations expected and did not meet targets for
case registration established by the national program.
The vast majority of registered cases (nearly 90%) between 2007
and 2010 were diagnosed and treated by the Secretary of Health.
Based on this information, we focus the remainder of our analysis
exclusively on SP as this is the insurance program that increasingly
provides care to these patients [38].
Antitrypanosomal medicine procurement and treatment
of cases. Since 2009, the national program has offered
medicines for treatment of registered cases at the state level by
requesting nifurtimox from the WHO-Bayer Nifurtimox Donation
Program. Our study found that procurement initiated in 2007 took
more than two years due to an inability of the national program to
secure all necessary importation and storage permits within
Mexico. Procurement initiated since 2009 has taken 4–6 months.
Once nifurtimox is received, the national program then provides it
on request to state Secretaries of Health, which in turn distribute
the allocated amount to the appropriate providers for the
treatment of identified patients [38]. The only exception to this
procurement process is that the Morelos state Program on Chagas
Disease chose to purchase benznidazole directly from Masters
Pharmaceuticals, Ltd. in 2010. This process took approximately
one year, with the medicines received in 2011.
Data from the national program indicate that, of the 1,329 cases
registered nationally in 2010–2011, 834 (62.7%) of these patients
received treatment; in addition, our analysis found that 120
(10.1%) of the cases were pending treatment at the end of 2011
due to an insufficient supply of nifurtimox, and the treatment
status of the remaining 375 (28.2%) was unknown [38]. All cases in
Mexico reported by the national program were treated with
nifurtimox except for those treated in the state of Morelos. No data
were available at the national level on the proportion of cases
treated prior to 2010–2011 or about the length, dosing and
efficacy of treatment provided.
Analysis of barriers at the national level
Table 2 provides a list of national level obstacles to treatment
access for Chagas disease, based on our analysis of data collected
in this study. The list includes all obstacles that were mentioned
during interviews and could be triangulated using a second data
source.
Regulation. Several regulatory obstacles at the national level
were identified. These included regulations regarding drug
authorization, medicine importation, and the lack of inclusion of
benznidazole and nifurtimox on the national formulary list.
According to Mexican law, all importers of medicines must
secure marketing authorization for the products they wish to
import [39]. The Federal Commission for Protection against
Health Risks (COFEPRIS) is the national medicines regulatory
authority and responsible for granting market authorization.
Neither benznidazole nor nifurtimox has a market authorization
in Mexico and a one-time importation permit must be obtained to
import either medicine into Mexico [40].
As both medicines are not marketed in Mexico, they are not
included in the national formulary and the institutional formular-
ies including SP formulary (CAUSES) [41].
Financing. The regulatory status of both benznidazole and
nifurtimox has important implications for financing available to
purchase these medicines. Their lack of COFEPRIS authorization
and exclusion from the national formulary and the SP formulary
precludes the usage of SP medicine procurement funds to
purchase them and leaves few avenues for funding [39]. In
addition, until 2012, Chagas disease was not included in the
package of interventions covered under SP (hereafter CAUSES)
for the reason stated above, further limiting financing available to
purchase medicines for treating Chagas disease [28].
The financing status of the medicines also affects the clinical
quality of treatment because nifurtimox can be procured at no cost
through the WHO-Bayer Nifurtimox Donation Program while
Treatment Access for Chagas Disease in Mexico
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Figure 3. Data on access to treatment for Chagas disease in Mexico, 2007–2011. Note on Figure 3: It was assumed that an additional 166
registered cases that the Secretary of Health reported in 2013 had been diagnosed and registered in 2011 but had not yet been confirmed at the time of the
initial data provision in January 2012.
doi:10.1371/journal.pntd.0002488.g003
Table 2. National level obstacles to treatment for Chagas disease in Mexico, by medicine.
Policy Intervention Benznidazole Nifurtimox
Regulation N Lack of national regulatory body (COFEPRIS) approval N Lack of national regulatory body (COFEPRIS) approval
N No commercial license, each importation requires a separate permit N No commercial license, each importation requires a
separate permit
N Not included in national formulary for Mexico (Cuadro Basico) N Not included in national formulary for Mexico (Cuadro
Basico)
Financing N Funds unavailable from Secretary of Health or SP to purchase Chagas
disease medicines
N Funds unavailable from Secretary of Health or SP to
purchase Chagas disease medicines
Payment N Medicine and donation costs fall to governmental agency N Medicine available for free, funds available through
donation program to support distribution costs
Organization N Mexican norms for vector borne diseases indicate use for acute and
chronic Chagas disease in patients up to 70 years old; name benznidazole
second-line therapy
N Mexican norms for vector borne diseases indicate use
for acute and chronic Chagas disease in patients up to 70
years old; name nifurtimox first-line therapy
N No national clinical guidelines for Chagas disease treatment N No national clinical guidelines for Chagas disease
treatment
N Chagas disease included in SP as of 2012 but drug excluded from
SP list (CAUSES)
N Chagas disease included in SP as of 2012 but drug
excluded from SP list (CAUSES)
N Benznidazole not on essential medicines list for Mexico N Nifurtimox not on essential medicines list for Mexico
N Global supply chain problems: insufficient global supply N Global supply chain problems: long waiting times
Persuasion
N Insufficient training and education of providers about Chagas
disease, its diagnosis and treatment
N Insufficient training and education of providers about
Chagas disease, its diagnosis and treatment
N Lack of political champion for the disease N Lack of political champion for the disease
underlined text represents differences in barriers to access between the two drugs.
doi:10.1371/journal.pntd.0002488.t002
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benznidazole is currently sold on the private market outside
Mexico and must be purchased [23,24].
Payment. As noted above, the WHO-Bayer Nifurtimox
Donation Program pays the costs for the medication, shipping,
and tariffs associated with its delivery. Although the national
Program on Onchocerciasis, Leishmaniasis and Chagas Disease
within CENAPRECE does not pay these direct costs for delivery
to Mexico, there are additional costs associated with drug
distribution within Mexico.
Organization. Our assessment of organization identified
several key challenges to access in this area, including the case
registration process, the status of the disease under SP, current
Chagas disease treatment guidelines, and problems with the
international supply chains for benznidazole and nifurtimox.
As per Figure 1, the case registration process requires that
patients receive at least three and sometimes four or more
diagnostic tests from two different labs before officially registering
a case. Of note, the state is responsible for registering new cases,
while the national level is responsible for confirming cases
identified at the state level and aggregating data reported by each
state on new cases registered. The current WHO diagnostic
guidelines recommend that samples be assayed using two distinct
tests before a confirmed diagnosis is made [12]. The additional
testing sourced from different labs can introduce significant delays
and costs between initial diagnosis and treatment in Mexico.
In terms of general policy guidance on the management of
Chagas disease, the Mexican Secretary of Health has established
official guidelines for the epidemiologic surveillance, prevention,
and control of vector-borne diseases that were updated in 2010
[42,43]. The 2010 policy guidelines for vector borne diseases state
that nifurtimox is the first-line antitrypanosomal therapy in
patients (up to 70 years of age) who have either acute or
indeterminate Chagas disease [43]. Comparison with the 2002
policy guidelines for vector borne diseases demonstrates that the
indications for antitrypanosomal therapy have been expanded to
include consideration of treatment in adults in the indeterminate
phase, as is consistent with the most recent scientific evidence
[9,17,42]. Though the most recent policy guidance provides
general support for the use of antitrypanosomal treatment,
Mexico’s national clinical guidelines database (CENETEC) for
physicians to use when treating patients do not provide
instructions on treatment of Chagas disease. Furthermore, neither
medicine is included on the Mexican essential medicines list,
though they are both included on the WHO Essential Medicines
List [44]. In 2012, Chagas disease was added to the SP CAUSES
under the group of ‘‘Remaining Infectious Diseases’’ [41], a
category that includes leishmaniasis and rickettsia, amongst others.
While the addition of Chagas disease to the CAUSES represents
an important step forward, it does not include any clinical
description of the disease course, nor does it name nifurtimox or
benznidazole as treatments [41].
Finally, supply chain problems for benznidazole and nifurtimox
that were reported for Mexico included long waiting times of 4
months to more than 2 years to procure either medicine from
sources outside the country, and a long, complex application
process to secure the necessary COFEPRIS importation permits
[45].
Persuasion. The primary challenge that was reported related
to the persuasion area is a lack of understanding and awareness of
the disease, its diagnosis, and treatment among health profession-
als and populations at risk. Although the Secretary of Health
provides physician and health worker trainings about Chagas
disease and some health education activities for the general public
[38], multiple key informants mentioned the lack of awareness and
understanding of Chagas disease by physicians, health workers and
the general population as well as fears or misconceptions about the
use of antitrypanosomal medicines among physicians as additional
obstacles to increasing diagnosis and treatment of Chagas disease
in Mexico. Existing evidence has shown a lack of understanding of
the disease among the general population physicians and health
workers. For example, studies in Morelos show that a substantial
proportion (about 45%) of the state population is aware of the
triatomine vectors that transmit T. cruzi, but few (about 15%) have
an understanding of the disease, its clinical consequences and how
to prevent and treat it [46,47]. Because both nifurtimox and
benznidazole are associated with adverse side effects, physician
and health worker concerns about treatment are not uncommon
[18,20,48]. Of note, the design and implementation of education
programs is a responsibility of the state Secretaries of Health; as
such there is substantial heterogeneity in these programs in
different states.
Other challenges: National prioritization. In addition to
these challenges, controversy has existed for several years
regarding estimates of the burden of Chagas disease in Mexico.
While epidemiologic studies estimate that the national prevalence
could be as high as 1.6% [49,50,51], important actors, including
some officials in the Secretary of Health, have stated in public
documents that data from the national blood bank indicate
Mexico has a much lower estimated national prevalence of 0.65%
or approximately 733,000 cases [52], and that Chagas disease
remains a focal problem that does not warrant significant national
attention [36]. These public statements highlight important
discord about the extent to which both health resources and
policy attention should be allocated to the control and treatment of
the disease.
Discussion
This study provides evidence regarding the extent of treatment
access for Chagas disease in Mexico and the barriers that influence
the level of access. In particular, the study demonstrates that the
number of Chagas disease cases registered at the national level in
Mexico since 2007 is approximately 0.41% of expected cases and
that 120 registered, eligible cases were awaiting treatment at the
time of the study. These findings also indicate that Mexico has
made an effort to register new cases and provide treatment at both
the state and national level and thus show an increased
commitment to addressing this disease in Mexico.
Our findings also demonstrate that epidemiologic surveillance
for Chagas disease remains a challenge in Mexico and that the
complexity of the case registration system may delay or limit
registration. Evidence from national data shows that problems in
the supply chain of medicines make it difficult to ensure timely
access to treatment as cases are registered and further, that the
medicine provided by the national program since 2009 has
exclusively been nifurtimox, a medicine that has been identified in
the clinical literature and international guidelines as second-line
therapy [20].
The lack of awareness and understanding of the disease and its
treatment among both physicians and populations at risk was
another important challenge related to the persuasion policy
intervention area [46]. Patient and provider awareness of the
disease has implications for efforts to strengthen epidemiologic
surveillance and the willingness of physicians to treat infected
patients when medicines are available. Additionally, access to
treatment for Chagas disease has until 2012 been further
weakened by its exclusion from the package of health interventions
that are covered under SP [27,28]. While its addition to the
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CAUSES in 2012 represents an important step (organization)
toward increasing access to treatment, clinical information about
the disease is still lacking in this document and neither
benznidazole nor nifurtimox is listed as a treatment for the
diseases in this category.
In addition to these barriers, it is important to acknowledge the
role of international actors and policies as barriers to access to
treatment for Chagas disease in Mexico and potentially in other
countries as well. The global shortage of benznidazole in 2011 and
the challenges in obtaining nifurtimox through WHO exist outside
the Mexican context but directly affect efforts by the Mexican
national and state control programs to increase access to treatment
[23,24].
These findings provide new information on the state of
treatment for Chagas disease in Mexico and the barriers that
prevent more widespread access. Previous work on this subject has
suggested that efforts to control and treat Chagas disease in
Mexico are insufficient [36,53] but no study has previously
measured the gap in access to treatment or analyzed related
obstacles. In addition, a recent study estimated the economic
burden associated with Chagas disease to exceed seven billion
dollars globally and several studies have described the need for
increased treatment globally [3,5,33,53,54]. This study is one of
the first to examine the multiple complex factors within the health
system that prevent more widespread treatment access in a
particular country setting. It is important to note, however, that
the state of Morelos did successfully procure benznidazole and
offers an important case for showing how a state can take
significant initiative in improving access to treatment for Chagas
disease.
Some of the findings from the Mexican experience may be
relevant to treatment access for Chagas disease in other countries
in the region. For instance, reliance on nifurtimox as a first-line
therapy in both the 2010 Mexican guidelines for vector-borne
diseases and in procurement of medicines at the national level
raises questions about the reasons for this choice and whether
other countries may also choose to procure nifurtimox through the
donation program now or in the future instead of purchasing
benznidazole through the private market. In the case of Mexico,
the regulatory status of the drugs, especially the lack of commercial
permits for them, and the exclusion of antitrypanosomal therapies
for Chagas disease from the Mexican national formulary have
severely limited sources of financing to buy benznidazole, causing
the national program to instead rely on the free nifurtimox.
However, little information exists about whether other countries
also rely on nifurtimox as a first-line therapy and if so, why.
Though clinical guidelines overwhelmingly suggest that benzni-
dazole is better tolerated and that the clinical evidence of its
efficacy is more robust, clear international consensus guidelines for
the treatment of Chagas disease have not been published and
relatively limited data are available about the use and clinical
outcomes for the two drugs by different countries around the
world.
There are several limitations to this study. First, data on the
prevalence of Chagas disease are limited both in Mexico and
globally. This constitutes an important challenge to efforts to
address this disease in Mexico. In this analysis, we use the official
2010 prevalence estimate from the Mexican Secretary of Health
because it is more conservative than the most recent WHO
estimate and because the WHO estimate does not have a clear
evidence base. This choice may result in our analysis showing
greater access to treatment (as a proportion of total infected cases)
than may actually exist in Mexico. Some actors within the
Mexican Secretary of Health have argued that the epidemiology of
Chagas disease in Mexico is focal and that states with a high
burden of disease should undertake activities to address this disease
at a state level, while others have maintained that the prevalence of
Chagas disease is substantial across much of the country and that
the disease should be a national priority, especially given the
migration of populations from endemic areas both within Mexico
and from neighboring countries to Mexico [36,50]. To provide a
more reliable estimate of national prevalence, a nationally
representative epidemiologic survey could be conducted, both
nationally and by state. This would advance efforts by both the
state and national programs to make more informed decisions
about the priority and resources that are warranted for Chagas
disease treatment.
A second limitation is that we consider benznidazole as the first
line antitrypanosomal medicine, despite the lack of definitive
international consensus on this issue. We made this decision
because benznidazole is being used exclusively as the reference
treatment regimen in clinical trials of new drugs, is named as the
first line therapy in the treatment guidelines of several non-
governmental organizations [20], and is cited as such in the vast
majority of the clinical literature [9,17,18]. It is worth noting,
however, that there is some diversity on treatment regimens within
Mexico. Although the national program has used nifurtimox from
the WHO donation program, the state of Morelos in Mexico has
purchased benznidazole for its treatment program. Morelos
registered 263 cases between 2007 and 2011, and treated 148
cases with benznidazole and 4 with nifurtimox.
This study was also limited by lack of data availability at the
national and global levels. At the national level in Mexico, this
included a lack of national treatment guidelines or data prior to
2010, a dearth of information about treatment eligibility or patient
refusal of treatment, and a lack of data on treatment dose,
completion or clinical outcomes. In particular, it was difficult to
determine what proportion of patients would be treatment eligible
according to the guidelines given that no data were available on
co-morbidities or patient clinical history that would allow a more
thorough analysis of patients in whom treatment may be
contraindicated. Furthermore, there is limited evidence about
access to treatment in other countries to provide a comparison for
assessing Mexico’s achievement in this area. Of note, however, a
recent study estimated that less than 1% of those infected with T.
cruzi receive treatment globally, suggesting that the extent of access
in Mexico is likely to be similar in other countries [5].
Based on these findings, there are three important strategies that
could be undertaken to increase access to treatment for Chagas
disease in Mexico.
First, under regulation, an effort could be made to ease the
importation process for these drugs. Ideally, this could be
accomplished by securing COFEPRIS approval for both medi-
cines and adding them to the national formulary, which could
require actions by the relevant producers of benznidazole and
nifurtimox. However, as noted above, benznidazole and nifurti-
mox are not approved by the United States Federal Drug
Administration or the European Medicines Agency, in part
because full clinical trials have not been completed for either
drug. This lack of approval from two leading regulatory bodies
may affect the willingness of other national regulatory bodies to
approve the medicines. That said, both medications are included
on the WHO Essential Medicine List [55]. In addition, clinical
evidence continues to accumulate in favor of these drugs and
efforts by institutions such as the Drugs for Neglected Diseases
Initiative are being made to register the drugs in countries such as
Colombia, Paraguay and Bolivia. In other contexts, alternative
regulatory approaches such as investigational protocols are being
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utilized to make the drugs available [18]. Also with respect to
regulation, countries with a high burden of Chagas disease may
consider instituting laws that mandate rigorous epidemiologic
surveillance and health education as well as prevention, diagnosis
and treatment of the disease. For instance, Argentina offers a
model for such legislation in National Law No. 26281. This law
requires, among other things mandatory diagnostic testing and
reporting for Chagas disease in all pregnant women and in
newborns in the first year of life born to infected mothers.
Second, under persuasion, efforts could be expanded to provide
disease-specific health education programs on Chagas disease for
physicians, healthcare providers and populations at risk. Increased
awareness of the disease and a better understanding of appropriate
treatment methods is a critical aspect of strengthening case
registration and access to treatment. In addition, health education
activities have been emphasized in other national control
programs such as those in Guatemala [56] and the Southern
Cone initiative and have been used alongside vector control to
increase awareness of the disease in high risk communities and
among physicians and health workers. Increased awareness of the
disease and of treatment methods is a critical aspect of
strengthening case registration and access to treatment. Given
the importance of this programming, the WHO and PAHO also
play a potentially important role in terms of encouraging these
programs and providing guidance on their design and implemen-
tation.
Third, under organization, it is important to strengthen existing
guidelines in Mexico for the diagnosis and treatment of Chagas
disease and information availability about the supply chains for
these two medicines. This includes the addition of a clinical
description of Chagas disease and the two medicines to its entry in
the CAUSES and the creation of a clinical guide for diagnosis and
treatment as this information is critically important to strengthen
awareness of treatment for Chagas disease and information for
practitioners about how to diagnose and treat the disease. In
addition, better public reporting of medicines released and used at
the state, national and global levels is needed.
In conclusion, this study found that access to treatment for
Chagas disease in one high burden country (Mexico) is limited in
important ways and identified three critical obstacles to treatment
access: regulatory barriers to importation, a lack of understanding
of the disease and its treatment, and a dearth of clinical guidelines
[5]. Several of these barriers are likely to affect access in other
countries as well, especially the lack of regulatory approval and
registration of benznidazole and nifurtimox and the lack of
publically available information on their supply chains. Finally, the
study proposed a series of actions that could be taken in Mexico,
based on a general analytical framework, to improve access to
treatment for Chagas disease. These recommendations have
important implications for other countries in the region with
similar problems in access to treatment for Chagas disease.
Acknowledgments
The authors would like to thank Dr. Veronika Wirtz, Dr. Michael Z. Levy,
Dr. Eric Dumonteil, Dr. Cristina Schulze and Dr. Carmel Salhi for their
input on this manuscript. We also appreciate comments from Dr. Pablo
Kuri of the Ministry of Health in Mexico.
Author Contributions
Conceived and designed the experiments: JMM CSS JMR MRR.
Performed the experiments: JMM CSS JMR. Analyzed the data: JMM
CSS JMR MRR. Contributed reagents/materials/analysis tools: JMM
CSS JMR MOS TB MRR. Wrote the paper: JMM CSS JMR MOS TB
MRR.
References
1. Mathers CD, Ezzati M, Lopez AD (2007) Measuring the burden of neglected
tropical diseases: the global burden of disease framework. PLoS Negl Trop Dis 1:
e114.
2. Tarleton RL, Reithinger R, Urbina JA, Kitron U, Gurtler RE (2007) The
challenges of Chagas Disease– grim outlook or glimmer of hope. PLoS Med 4:
e332.
3. Lee BY, Bacon KM, Bottazzi ME, Hotez PJ (2013) Global economic burden of
Chagas disease: a computational simulation model. Lancet Infect Dis 13: 342–
348.
4. World Health Organization (2002) Control of Chagas Disease: Second report of
the WHO Expert Committee. Geneva: World Health Organization.
5. Ribeiro I, Sevcsik AM, Alves F, Diap G, Don R, et al. (2009) New, improved
treatments for chagas disease: from the R&D pipeline to the patients. PLoS Negl
Trop Dis 3: e484.
6. Pan American Health Organization (2006) Estimacion cuantitativa de la
enfermedad de Chagas en las Americas. Montevideo, Uruguay: WHO
Department of Control of Neglected Tropical Diseases.
7. Roberts MJ, Reich MR (2011) Pharmaceutical Reform: A Guide to Improving
Performance and Equity. Washington, DC: The World Bank.
8. Hoff R, Teixeira RS, Carvalho JS, Mott KE (1978) Trypanosoma cruzi in the
cerebrospinal fluid during the acute stage of Chagas’ disease. N Engl J Med 298:
604–606.
9. Bern C, Montgomery SP, Herwaldt BL, Rassi A, Jr., Marin-Neto JA, et al.
(2007) Evaluation and treatment of chagas disease in the United States: a
systematic review. JAMA 298: 2171–2181.
10. Comisio´n Nacional de Proteccio´n Social en Salud (2011) Familias y Beneficiarios
por Localidad al Segundo Semestre 2011. Comisio´n Nacional de Proteccio´n
Social en Salud.
11. Lescure FX, Le Loup G, Freilij H, Develoux M, Paris L, et al. (2010) Chagas
disease: changes in knowledge and management. Lancet Infect Dis 10: 556–570.
12. World Health Organization (2007) WHO Consultation on International
Biological Reference Preparations for Chagas Diagnostic Tests. Geneva,
Switzerland: World Health Organization,.
13. World Health Assembly (2010) Chagas disease: control and elimination. World
Health Assembly,.
14. Carlier Y, Torrico F, Sosa-Estani S, Russomando G, Luquetti A, et al. (2011)
Congenital Chagas disease: recommendations for diagnosis, treatment and
control of newborns, siblings and pregnant women. PLoS Negl Trop Dis 5:
e1250.
15. de Andrade AL ZF, de Oliveira RM, Almeida Silva S, Luguetti A, et al (1996)
Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma
cruzi infection. Lancet 348.
16. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, et al. (2006) Long-term
cardiac outcomes of treating chronic Chagas disease with benznidazole versus no
treatment: a nonrandomized trial. Ann Intern Med 144: 724–734.
17. Rassi A, Jr., Rassi A, Marin-Neto JA (2010) Chagas disease. Lancet 375: 1388–
1402.
18. Bern C (2011) Antitrypanosomal therapy for chronic Chagas’ disease.
N Engl J Med 364: 2527–2534.
19. Sosa-Estani S, Viotti R, Segura EL (2009) Therapy, diagnosis and prognosis of
chronic Chagas disease: insight gained in Argentina. Mem Inst Oswaldo Cruz
104 Suppl 1: 167–180.
20. Yun O, Lima MA, Ellman T, Chambi W, Castillo S, et al. (2009) Feasibility,
drug safety, and effectiveness of etiological treatment programs for chagas
disease in honduras, guatemala, and bolivia: 10-year experience of medecins
sans frontieres. PLoS Negl Trop Dis 3: e488.
21. Marin-Neto JA, Rassi A, Jr., Avezum A, Jr., Mattos AC, Rassi A, et al. (2009)
The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial
for patients with chronic Chagas heart disease. Mem Inst Oswaldo Cruz 104
Suppl 1: 319–324.
22. National Institutes of Health (2009) BENEFIT: Evaluation of the Use of
Antiparasitic Drug (Benznidazole) in the Treatment of Chronic Chagas Disease.
Available: http://clinicaltrials.gov/show/NCT00123916. Accessed 16 Septem-
ber 2013.
23. Manne J, Snively CS, Levy MZ, Reich MR (2012) Supply chain problems for
Chagas disease treatment. Lancet Infect Dis 12: 173–175.
24. Medecins Sans Frontieres (2011) Briefing Document: Shortage of Benznidazole
Leaves Thousands of Chagas Patients Without Treatment. Medecins Sans
Frontieres.
25. World Pharma News (2011) Bayer extends support to fight Chagas disease.
Available: http://press.healthcare.bayer.com/en/press/auth/news-details-page.
php/14107/2011-0114. Accessed 16 September 2013.
26. Instituto Nacional de Estadistica y Geografia (INEGI) (2010) Censo de
Poblacion y Vivienda 2010. Mexico.
Treatment Access for Chagas Disease in Mexico
PLOS Neglected Tropical Diseases | www.plosntds.org 9 October 2013 | Volume 7 | Issue 10 | e2488
27. Frenk J, Gonzalez-Pier E, Gomez-Dantes O, Lezana MA, Knaul FM (2006)
Comprehensive reform to improve health system performance in Mexico.
Lancet 368: 1524–1534.
28. Comision Nacional de Proteccion Social en Salud (2011) Catalogo Universal de
Servicios de Salud In: Seguro Popular, editor: Secretaria de Salud - Estados
Unidos Mexicanos.
29. Chertorivski S (2011) Detras esta la gente. El Universal. Available: http://www.
eluniversal.com.mx/editoriales/53752.html. Accessed 16 September 2013.
30. Aday LA, Andersen R (1974) A framework for the study of access to medical
care. Health Serv Res 9: 208–220.
31. Hanson K, Random MK, Oliveira-Cruz V, Mills A (2003) Expanding access to
priority health interventions: a framework for understanding the constraints to
scaling-up. Journal of International Development 15: 1–14.
32. Frost LJ, Reich MR (2008) Access: How Do Good Health Technologies Get to
Poor People in Poor Countries. Cambridge: Harvard Center for Population and
Development Studies, distributed by Harvard University Press.
33. Drugs for Neglected Diseases Initiative (2012) Azoles E1224 & Biomarker
(Chagas). Available: http://www.dndi.org/diseases-projects/portfolio/azoles-
e1224.html. Accessed 16 September 2013.
34. Maxwell JA (2005) Qualitative Research Design: An Interactive Approach.
Thousand Oaks, California: Sage Publications.
35. Fielding NG, Fielding JL (1986) Linking Data. Beverly Hills, California: Sage
Publications.
36. Attaran A (2006) Chagas’ disease in Mexico. Lancet 368: 1768; discussion 1768–
1769.
37. Kuri Morales P (2013) Follow-up to Ministers Leadership in Health Forum at
Harvard. In: Michael Reich, editor. Mexico, D.F. pp. 1.
38. Direccion del Programa de Enfermedades Transmitidas por Vector (2011)
Programa de Enfermedad de Chagas. Mexico City, DF: Subsecretaria de
Prevencion y Promocion de la Salud - Centro Nacional de Programas
Preventivos y Control de Enfermedades.
39. Moise P, Docteur E (2007) Pharmaceutical Pricing and Reimbursement Policies
in Mexico. Paris, France: Organization for Economic Cooperation and
Development.
40. Comision Federal Para la Proteccion Contra Riesgos Sanitarios (2010)
Comprobante de Tramite (COFEPRIS-01-010-C). In: Secretaria de Salud,
editor.
41. Comision Nacional de Proteccion Social en Salud/Seguro Popular (2012)
Catalogo Universal de Servicios de Salud (CAUSES 2012). Mexico, DF:
Comision Nacional de Proteccion Social en Salud.
42. Estados Unidos Mexicanos Secretarı´a de Salud (2002) Norma Oficial Mexicana
para la vigilancia epidemiologica, prevencion, y control de enfermedades
transmitidas por vector. In: Comite´ Consultivo Nacional de Normalizacio´n de
Prevencio´n y Control de Enfermedades, editor: Secretaria de Salud,.
43. Estados Unidos Mexicanos Secretarı´a de Salud (2010) Norma Oficial Mexicana
para la vigilancia epidemiologica, prevencion y control de las enfermedades
transmitidas por vector. Comite´ Consultivo Nacional de Normalizacio´n de
Prevencio´n y Control de Enfermedades.
44. Centro Nacional de Excelencia Technologica en Salud (2011) Guias de Practica
Clinica. Secretaria de Salud de Mexico.
45. Medecins San Frontieres (2009) Patient Advocacy and Access to Care - Breaking
Through the Barriers. Chagas Disease: Break the Silence, Time to Treat:
Medecins San Frontieres.
46. Ramsey JM, Alvear AL, Ordonez R, Munoz G, Garcia A, et al. (2005) Risk
factors associated with house infestation by the Chagas disease vector Triatoma
pallidipennis in Cuernavaca metropolitan area, Mexico. Med Vet Entomol 19:
219–228.
47. Ramsey JM (2005) La Enfermedad de Chagas en Oaxaca: Una estrategia
educativa y eco-epidemiologia. Instituto Nacional de Salud Publica.
48. Jackson Y, Alirol E, Getaz L, Wolff H, Combescure C, et al. (2010) Tolerance
and safety of nifurtimox in patients with chronic chagas disease. Clin Infect Dis
51: e69–75.
49. Guzman-Bracho C (2001) Epidemiology of Chagas disease in Mexico: an
update. Trends Parasitol 17: 372–376.
50. Ramsey JM (2007) Chagas disease Transmission in Mexico: A case for
translational research, while waiting to take disease burden seriously.
Cuernavaca, Mexico: Salud Publica de Mexico.
51. Guzman Bracho C, Garcia Garcia L, Floriani Verdugo J, Guerrero Martinez S,
Torres Cosme M, et al. (1998) [Risk of transmission of Trypanosoma cruzi by
blood transfusion in Mexico]. Rev Panam Salud Publica 4: 94–99.
52. Novelo-Garza BA, Benitez-Arvizu G, Pena-Benitez A, Galvan-Cervantes J,
Morales-Rojas A (2010) [Detection of Trypanosoma cruzi in blood donors]. Rev
Med Inst Mex Seguro Soc 48: 139–144.
53. Moncayo A, Silveira AC (2009) Current epidemiological trends for Chagas
disease in Latin America and future challenges in epidemiology, surveillance and
health policy. Mem Inst Oswaldo Cruz 104 Suppl 1: 17–30.
54. Villar JC (2001) Commentary: Control of Chagas’ disease: let’s put people
before vectors. Int J Epidemiol 30: 894–895.
55. World Health Organization (2013) WHO Model List of Essential Medicines.
18th List ed: World Health Organization.
56. Hashimoto K, Kojima M, Nakagawa J, Yamagata Y (2005) Effectiveness of
Health Education through Primary School Teachers: Activities of Japan
Overseas Cooperation Volunteers in the Control of Chagas’ Disease Vectors
in Guatemala. Technology and Development 18: 71–76.
Treatment Access for Chagas Disease in Mexico
PLOS Neglected Tropical Diseases | www.plosntds.org 10 October 2013 | Volume 7 | Issue 10 | e2488
